OncoSec Medical Inc (ONCSQ)

[hschlauch]

In the case of advanced metastatic melanoma with visceral lesions, you won't need to electroporate the visceral lesions directly if there is an accessible cutaneous lesion. The point of Oncosec's electoroporation platform is to drive a systemic immune response. Once you drive that immune response, the activated T-cells will target for destruction those tumor cells that carry matching antigens; this is how the abscopal effect works. Because the visceral tumors carry the same "fingerprints" as the electroporated tumor, they too will be targeted once the T cells become activated with the tumor matching neoantigens.

For cancers that don't have cutaneous lesions, Oncosec has developed technology that supposedly works with any tissue condition and optimizes protein expression. Oncosec has reportedly been able to successfully express over fifty different proteins intratumorally in preclinical models using this new technology.